I truly believe that what we call the field of advanced therapies – so that’s cells, genes or cells plus genes – is going to provide benefit to patients over the next 5 to 10 years.
I'am EMBO Director (European Molecular Biology Organization), a group leader at EMBL Heidelberg and Professor at King’s College London.